SUNITCAP 50 mg contains Sunitinib malate, an oral targeted anticancer medicine. It is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks receptors involved in tumor growth, angiogenesis (blood vessel formation), and cancer cell survival, thereby slowing cancer progression.

Sunitinib is used in adults for the treatment of:

1. Advanced / metastatic Renal Cell Carcinoma (RCC)

2. Gastrointestinal Stromal Tumor (GIST)
    – After failure or intolerance to imatinib

3. Pancreatic Neuroendocrine Tumors (pNETs)
    – Unresectable or metastatic, well-differentiated 

Common side effects:

•   Fatigue, weakness

•   Diarrhea

•   Nausea and vomiting

•   Decreased appetite, weight loss

•   Hypertension

•   Hand–foot syndrome

•   Mouth ulcers (stomatitis)

•   Skin and hair color changes

Serious side effects:

•   Cardiac toxicity (reduced LVEF, heart failure)

•   Severe hypertension

•   Thyroid dysfunction (hypothyroidism)

•   Bleeding or thromboembolic events

•   Liver toxicity

 Regular monitoring of blood pressure, thyroid function, liver function, and cardiac status is mandatory.

Dosage is based on indication and patient tolerance.

Standard dosing:

•   50 mg once daily for 4 weeks ON, 2 weeks OFF
    (One treatment cycle = 6 weeks)

Alternative dosing:

•   37.5 mg once daily continuously (commonly in pNETs)

    Dose reduction may be done using 25 mg or 12.5 mg capsules if toxicity occurs.


NOTE: This medicine should be taken only under a doctor’s supervision.